510(k) Report

510(k) · Cleared

Cleared

BioWaveGO RX

K210202510(k) SpecialCleared Feb 24, 202130-day reviewClass II21 CFR 882.5890

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Biowave Corporation · GZJ Stimulator, Nerve, Transcutaneous, For Pain Relief

Cleared on Feb 24, 2021 as substantially equivalent to K180943 (Biowave Corporation, 2018) after a 30-day review. Its family tree reaches back 2 generations to 2015.

Decided
Feb 24, 2021
Review
30 days
Class
Class II
Product code
GZJ
Recalls
None
Predicates
1

Its longest line of descent runs back 2 generations to K152437 (2015). No later device cites it as a predicate yet.

  1. Root · 2 generations backK152437 BiowaveHOME Neuromodulation Pain Therapy DeviceBiowave Corporation · 2015
  2. 1 generation backK180943 BioWaveGOBiowave Corporation · 2018
  3. This deviceK210202 BioWaveGO RXBiowave Corporation · 2021
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−2K152437BiowaveHOME Neuromodulation Pain Therapy DeviceBiowave Corporation2015—
−1K180943BioWaveGOBiowave Corporation2018—
0 (this device)K210202BioWaveGO RXBiowave Corporation2021—
FIG. 1 — Lineage of K210202, 2015–2021Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in GZJ? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new GZJ device

  1. #1 K252767 actiTENS miniscore 13.1 · 9 generations · no Class I recall
  2. #2 Held for the reportin the report
  3. #3 Held for the reportin the report
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K180943BioWaveGO
Summary page 5
…soidal signals between electrodes, providing symptomatic relief of acute, chronic, and post-operative pain. The device is identical in design to the BioWaveGO cleared in K180943. However, this 510(k) seeks clearance of the device for prescription use. The BioWaveGO Rx has the identical battery and software…
Biowave Corporation2018—
†K152437BiowaveHOME Neuromodulation Pain Therapy DeviceBiowave Corporation2015—

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • The line of descent spans 6 years and passes through 1 company; a new generation was cleared every 2.9 years on median.
  • None of the 2 ancestors has a recall.

How does its category compare?

All GZJ devices

GZJ Stimulator, Nerve, Transcutaneous, For Pain Relief: FDA decisions, review times, recalls and adverse event reports over 20 years. 2021, this device’s year, is highlighted.

FDA decisions per year · GZJ

1in 2025

2007: 132008: 112009: 162010: 52011: 52012: 122013: 22014: 42015: 32016: 32017: 32018: 22019: 32020: 42021: 32022: 42023: 12024: 32025: 12026 (partial year): 2
2007high 16 (2009) · low 1 (2023)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · GZJ

207in 2024

2007: 223 days median2008: 136 days median2009: 155 days median2010: 232 days median2011: 168 days median2012: 154 days median2014: 344 days median2015: 202 days median2016: 163 days median2017: 113 days median2019: 156 days median2020: 183 days median2021: 231 days median2022: 175 days median2024: 207 days median
2007high 344 (2014) · low 113 (2017)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · GZJ

1in 2011

2007: 42008: 12011: 1
2007high 4 (2007) · low 0 (2009)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · GZJ

13in 2025

2007: 42008: 452009: 172010: 222011: 222012: 202013: 102014: 232015: 182016: 322017: 582018: 212019: 72020: 102021: 52022: 42023: 392024: 122025: 13
2007high 58 (2017) · low 4 (2007)2025

MAUDE reports naming product code GZJ, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20071322344
200811136145
200916155017
20105232022
20115168122
201212154020
20132—010
20144344023
20153202018
20163163032
20173113058
20182—021
2019315607
20204183010
2021323105
2022417504
20231—039
20243207012
20251—013
20262—0—

What is it indicated for?

The BioWaveGO Rx is indicated for prescription use for:

* Symptomatic relief of chronic, intractable pain

* Symptomatic relief of acute pain

* As an adjunctive treatment in the management of post-surgical and post-traumatic acute pain

Indications for use as stated in the FDA summary.

Cite this page

510(k) Report. “K210202: BioWaveGO RX.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K210202

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026